IL37588A - 2h-pyrimido (2,1-a) isoquinolin-2-ones,their preparation and pharmaceutical compositions containing them - Google Patents
2h-pyrimido (2,1-a) isoquinolin-2-ones,their preparation and pharmaceutical compositions containing themInfo
- Publication number
- IL37588A IL37588A IL37588A IL3758871A IL37588A IL 37588 A IL37588 A IL 37588A IL 37588 A IL37588 A IL 37588A IL 3758871 A IL3758871 A IL 3758871A IL 37588 A IL37588 A IL 37588A
- Authority
- IL
- Israel
- Prior art keywords
- addition salt
- acid addition
- formula
- isoquinoline
- compound
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 40
- 239000002253 acid Substances 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 30
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 14
- -1 alkyl acrylate ester Chemical class 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- HJEUQDNUAGJVIX-UHFFFAOYSA-N 3,4,6,7-tetrahydropyrimido[2,1-a]isoquinolin-2-one Chemical compound O=C1N=C2N(CCC3=CC=CC=C23)CC1 HJEUQDNUAGJVIX-UHFFFAOYSA-N 0.000 claims description 4
- POWYVQZJNFQFGI-UHFFFAOYSA-N 3,4-dihydropyrimido[2,1-a]isoquinolin-2-one Chemical compound O=C1N=C2N(C=CC3=CC=CC=C23)CC1 POWYVQZJNFQFGI-UHFFFAOYSA-N 0.000 claims description 4
- 238000000354 decomposition reaction Methods 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 230000000269 nucleophilic effect Effects 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000012433 hydrogen halide Substances 0.000 claims 2
- 229910000039 hydrogen halide Inorganic materials 0.000 claims 2
- 241000532353 Porzana Species 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 15
- OSILBMSORKFRTB-UHFFFAOYSA-N isoquinolin-1-amine Chemical compound C1=CC=C2C(N)=NC=CC2=C1 OSILBMSORKFRTB-UHFFFAOYSA-N 0.000 description 9
- 238000001953 recrystallisation Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- BGAJZISBCWKHSD-UHFFFAOYSA-N 3-(1-iminoisoquinolin-2-yl)propanoic acid Chemical compound N=C1N(C=CC2=CC=CC=C12)CCC(=O)O BGAJZISBCWKHSD-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- SXULEUOIZFHQLM-UHFFFAOYSA-N 1,3,4,6,7,11b-hexahydropyrimido[2,1-a]isoquinolin-2-one Chemical compound O=C1NC2N(CCC3=CC=CC=C23)CC1 SXULEUOIZFHQLM-UHFFFAOYSA-N 0.000 description 1
- NQUVCFXSWZGQPY-UHFFFAOYSA-N 2h-pyrimido[2,1-a]isoquinoline Chemical compound C1=CC=C2C3=NCC=CN3C=CC2=C1 NQUVCFXSWZGQPY-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HDZKTMAAJYURAD-UHFFFAOYSA-N 4h-pyrimido[2,1-a]isoquinoline Chemical class C1=CC=C2C3=NC=CCN3C=CC2=C1 HDZKTMAAJYURAD-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 235000003339 Nyssa sylvatica Nutrition 0.000 description 1
- 244000018764 Nyssa sylvatica Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- IYRMNDOLPONSCJ-UHFFFAOYSA-N isoquinolin-2-ium;chloride Chemical compound Cl.C1=NC=CC2=CC=CC=C21 IYRMNDOLPONSCJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDUZXMHHZYBCED-UHFFFAOYSA-N pyrimido[2,1-a]isoquinolin-2-one Chemical compound C1=CC=C2C3=NC(=O)C=CN3C=CC2=C1 BDUZXMHHZYBCED-UHFFFAOYSA-N 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB4140270A GB1356937A (en) | 1970-08-27 | 1970-08-27 | Pyrimido-isoquinolines |
| GB5678170 | 1970-11-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL37588A0 IL37588A0 (en) | 1971-11-29 |
| IL37588A true IL37588A (en) | 1974-09-10 |
Family
ID=26264669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL37588A IL37588A (en) | 1970-08-27 | 1971-08-26 | 2h-pyrimido (2,1-a) isoquinolin-2-ones,their preparation and pharmaceutical compositions containing them |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US3792050A (OSRAM) |
| AR (3) | AR192890A1 (OSRAM) |
| BE (1) | BE771911A (OSRAM) |
| CA (1) | CA977343A (OSRAM) |
| DE (1) | DE2142792A1 (OSRAM) |
| ES (2) | ES394546A1 (OSRAM) |
| FR (1) | FR2103559B1 (OSRAM) |
| GB (1) | GB1356937A (OSRAM) |
| IE (1) | IE35570B1 (OSRAM) |
| IL (1) | IL37588A (OSRAM) |
| NL (1) | NL7111759A (OSRAM) |
| SE (1) | SE373138B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3868378A (en) * | 1973-06-06 | 1975-02-25 | Morton Norwich Products Inc | Imidazo {8 4,5-f{9 {0 quinolin-9-ols |
| US3919238A (en) * | 1973-06-06 | 1975-11-11 | Morton Norwich Products Inc | 9-(Substituted amino)imidazo(4,5-f) quinolines |
| US4017625A (en) * | 1975-08-01 | 1977-04-12 | Pfizer Inc. | Anti-allergic N-(5-tetrazolyl)-1-oxo-1H-6-alkoxypyrimido-[1,2-a]quinoline-2-carboxamides and intermediates therefor |
| US4127720A (en) * | 1977-09-21 | 1978-11-28 | Bristol-Myers Company | Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity |
-
1970
- 1970-08-27 GB GB4140270A patent/GB1356937A/en not_active Expired
-
1971
- 1971-08-26 IL IL37588A patent/IL37588A/en unknown
- 1971-08-26 DE DE19712142792 patent/DE2142792A1/de active Pending
- 1971-08-26 SE SE7110810A patent/SE373138B/xx unknown
- 1971-08-26 FR FR7131030A patent/FR2103559B1/fr not_active Expired
- 1971-08-26 AR AR237590A patent/AR192890A1/es active
- 1971-08-26 ES ES394546A patent/ES394546A1/es not_active Expired
- 1971-08-26 IE IE1082/71A patent/IE35570B1/xx unknown
- 1971-08-26 US US00175329A patent/US3792050A/en not_active Expired - Lifetime
- 1971-08-26 NL NL7111759A patent/NL7111759A/xx unknown
- 1971-08-26 CA CA121,468A patent/CA977343A/en not_active Expired
- 1971-08-27 BE BE771911A patent/BE771911A/xx unknown
-
1972
- 1972-05-11 AR AR241934A patent/AR195669A1/es active
- 1972-05-11 AR AR241935A patent/AR193522A1/es active
-
1974
- 1974-01-16 ES ES422327A patent/ES422327A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CA977343A (en) | 1975-11-04 |
| AR192890A1 (es) | 1973-03-21 |
| FR2103559A1 (OSRAM) | 1972-04-14 |
| IE35570B1 (en) | 1976-03-18 |
| AR193522A1 (es) | 1973-04-30 |
| SE373138B (OSRAM) | 1975-01-27 |
| ES394546A1 (es) | 1974-09-01 |
| AR195669A1 (es) | 1973-10-31 |
| IL37588A0 (en) | 1971-11-29 |
| US3792050A (en) | 1974-02-12 |
| GB1356937A (en) | 1974-06-19 |
| FR2103559B1 (OSRAM) | 1974-09-06 |
| BE771911A (fr) | 1972-12-28 |
| DE2142792A1 (de) | 1972-03-02 |
| ES422327A1 (es) | 1976-08-01 |
| NL7111759A (OSRAM) | 1972-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2919030B2 (ja) | キノン誘導体 | |
| PT88899B (pt) | Provesso para a preparacao de tetrahidro-furo {2,3-c}piridinas e de tetrahidro--tieno {2,3-c}piridinas e de composicoes farmaceuticas que as contem | |
| EP0018104B1 (en) | Tetrahydroisoquinolines, their production and the compounds and pharmaceutical compositions containing them for use in the prevention or treatment of hypertension | |
| AU655634B2 (en) | New active compounds | |
| PT723544E (pt) | Carbamatos de alcoxialquilo de imidazo¬1,2-a|piridinas | |
| EP0198456A2 (en) | 1,7-Naphthyridine derivatives and medicinal preparations containing same | |
| EP0040860B1 (en) | Dibenzoxazepine derivative, process for preparing the same and pharmaceutical composition comprising the same | |
| JPS6254109B2 (OSRAM) | ||
| US3123618A (en) | Io-dihydroanthkacene-z | |
| EP0003016B1 (en) | Pyrazino-benzoxazepine and -benzthiazepine derivatives, processes for their production and pharmaceutical compositions containing them | |
| EP0816338B1 (en) | 3-(bis-substituted-phenylmethylene)oxindole derivatives | |
| IL37588A (en) | 2h-pyrimido (2,1-a) isoquinolin-2-ones,their preparation and pharmaceutical compositions containing them | |
| GB1586655A (en) | Pyrido-indole transquilising agents | |
| JPH0352465B2 (OSRAM) | ||
| JP2834506B2 (ja) | 新規チエニルオキシ‐アルキルアミン誘導体、その製法及びこの化合物を含有する医薬 | |
| US3923996A (en) | 3-Substituted-oxindoles in compositions and methods of treating obesity | |
| US3598829A (en) | Certain isoxazolylpyridines and isothiazolylpyridines | |
| Hori et al. | Novel nonnarcotic analgesics with an improved therapeutic ratio. Structure-activity relationships of 8-(methylthio)-and 8-(acylthio)-1, 2, 3, 4, 5, 6-hexahydro-2, 6-methano-3-benzazocines | |
| JPH06511015A (ja) | 複素環式誘導体 | |
| JPH02501926A (ja) | 置換されたアザシクロヘキシル誘導体 | |
| US3876788A (en) | Heterocyclic compounds in the treatment of inflammatory of arthritic conditions | |
| IE47794B1 (en) | Process for the preparation of thieno(2,3-c)-and(3,2-c)-pyridines | |
| US3917833A (en) | Amino-substituted benzocycloheptenones for inducing sleep | |
| US3209007A (en) | (dibenzo (a, d) 1, 4-cycloheptene-5-yloxy) amines | |
| US3880863A (en) | 17-Aralkyl-6 beta-azido-4,5 alpha-epox-ymorphinan-3-01{hu s |